Release Date: 2024-05-30
Psychopharmacology of Depression
Sevval Dicle Pakdemir (Author), Mehmet Gunes (Author)
Release Date: 2024-05-30
his chapter presents a comprehensive review of the psychopharmacology of depression. It discusses the prevalence and impacts of depression, emphasizing that antidepressant drugs are effective treatments. Starting from traditional treatments like monoamine oxidase inhibitors (MAO-Is) and tricyclic antidepressants (TCAs), it moves on to newer options like selective serotonin reuptake inhibitors (SSRIs) and selective serotonin-norepinephrine reuptake [...]
Media Type
Buy from
Price may vary by retailers
| Work Type | Book Chapter |
|---|---|
| Published in | Depression Treatment Updates |
| First Page | 25 |
| Last Page | 45 |
| DOI | https://doi.org/10.69860/nobel.9786053359456.2 |
| Page Count | 21 |
| Copyright Holder | Nobel Tıp Kitabevleri |
| License | https://nobelpub.com/publish-with-us/copyright-and-licensing |
Sevval Dicle Pakdemir (Author)
Research Assistant, Dicle University
https://orcid.org/0000-0002-0447-0187
3Dr. Şevval Dicle Pakdemir entered Diyarbakır Dicle University Faculty of Medicine in 2016, graduated in 2022, and received the title of Medical Doctor. She worked as a general practitioner at Diyarbakır Selahaddin Eyyubi State Hospital for 3 months of compulsory service. She started working as an assistant physician in the Psychiatry Department of Istanbul Başakşehir Çam and Sakura City Hospital in January 2023 and has been working at Dicle University Psychiatry Department since March 2023. She is a member of 1 organization related to her profession.
Mehmet Gunes (Author)
Associate Professor, Dicle University
https://orcid.org/0000-0003-3979-5990
3Associate Professor Mehmet Güneş graduated from Çukurova University Faculty of Medicine in 2001 and received the title of Doctor of Medicine. He worked as a general practitioner at Şanlıurfa/Birecik central health center between 2001-2003. He did his military service in the Subatan border battalion in Kars province between 2003-2004. In 2005, Harran University started its mental health and diseases specialty training in the USA. I graduated from Harran University Faculty of Medicine in 2009 and received the title of Psychiatrist. He worked as a Mental Health and Diseases Specialist at Şanlıurfa/Birecik State Hospital during his compulsory service obligation in 2009-2011. In 2012, he started working as an Assistant Professor in the Department of Psychiatry at Dicle University Faculty of Medicine. He has articles published in domestic and international journals.
WHO. Depression Fact Sheet. 2017.
Malhi GS & Mann JJ. Depression Lancet 2018; 392, 2299–2312 .
Burcusa SL & Iacono WG. Risk for recurrence in depression. Clin. Psychol. Rev. 2007;27, 959–985 Monroe, S. M. & Harkness, K. L. Life stress, the “kindling” hypothesis, and the recurrence of depression: considerations from a life stress perspective. Psychol. Rev. 2005;112, 417–445 .
Lopez-Munoz F, Alamo C. Monoaminergic neurotransmission: the history of the discovery of antidepressants from the 1950s until today. Curr Pharm Des. 2009;15: 1563e1586.
Gaynes BN, Warden D, Trivedi MH, Wisniewski SR, Fava M, Rush AJ. What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression. Psychiatr Serv. 2009;60:1439-1445.
Hirschfeld RM. History and evolution of the monoamine hypothesis of depression. J Clin Psychiatry. 2000;61(suppl 6):4e6.
Hasselbalch BJ, Knorr U, Hasselbalch SG, Gade A, Kessing LV. Cognitive deficits in the remitted state of unipolar depressive disorder. Neuropsychology. 2012;26: 642e651
.
Stahl SM, Felker A. Monoamine oxidase inhibitors: a modern guide to an unrequited class of antidepressants. CNS Spectr. 2008;13(10):855e870.
Pletscher A. The discovery of antidepressants: a winding path. Experientia. 1991;47(1):4e8.
Cleare A et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2008 British Association for Psychopharmacology guidelines. J. Psychopharma
David DJ & Gourion D. [Antidepressant and tolerance: determinants and management of major side effects]. Encephale 2016; 42, 553–561 .
Richelson E. Antimuscarinic and other receptor-blocking properties of antidepressants. Mayo Clin. P
Hisaoka K et al. Tricyclic antidepressant amitriptyline activates fibroblast growth factor receptor signaling in glial cells: involvement in glial cell linederived neurotrophic factor production. J. Biol. Chem. 2011; 286, 21118–21128 .
Morioka N et al. Amitriptyline up-regulates connexin43-gap junction in rat cultured cortical astrocytes via activation of the p38 and c-Fos/AP-1 signalling pathway. Br. J. Pharmacol. 2014; 171, 2854–2867 .
Budzinski ML et al. Tricyclic antidepressants target FKBP51 SUMOylation to restore glucocorticoid receptor activity. Mol. Psychiatry 2022; 27, 2533–2545 .
Barbey JT, Roose SP. SSRI safety in overdose. J Clin Psychiatry. 1998;59(suppl 15):42e48.
Cleare A et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2008 British Association for Psychopharmacology guidelines. J. Psychopharmacol.2015;29, 459–525 .
Malison RT et al. Reduced brain serotonin transporter availability in major depression as measured by [123I]-2 beta-carbomethoxy-3 beta-(4-iodophenyl) tropane and single photon emission computed tomography. Biol. Psychiatry 1998;44, 1090–1098 .
Scorza MC et al. Preclinical and clinical characterization of the selective 5- HT(1A) receptor antagonist DU-125530 for antidepressant treatment. Br. J. Pharmacol. 2012; 167, 1021–1034
Cremers TI et al. Inactivation of 5-HT(2C) receptors potentiates consequences of serotonin re-uptake blockade. Neuropsychopharmacology 2004; 29, 1782–1789
Szabo ST, de Montigny C & Blier P. Modulation of noradrenergic neuronal firing by selective serotonin re-uptake blockers. Br. J. Pharmacol. 1999;126, 568–571 .
Casarotto PC et al. Antidepressant drugs act by directly binding to TRKB neurotrophin receptors. Cell, 2021;184, 1299–1313.e1219 .
Celada P, Puig MV, Amargós-Bosch M, Adell A, Artigas F. The therapeutic role of 5-HT1A and 5-HT2A receptors in depression. J Psychiatry Neurosci. 2004;29(4):252e265
James SP, Mendelson WB. The use of trazodone as a hypnotic: a critical review. J Clin Psychiatry. 2004;65(6): 752e755.
Rosenblat JD, McIntyre RS, Alves GS, Fountoulakis KN, Carvalho AF. Beyond monoamines-novel targets for treatment-resistant depression: a comprehensive review. Curr Neuropharmacol. 2015;13(5):636e655.
Himmerich H, Minkwitz J, Kirkby KC. Weight gain and metabolic changes during treatment with antipsychotics and antidepressants. Endocr Metab Immune Disord - Drug Targets. 2015;15:252e260.
Garland EJ, Remick RA, Zis AP. Weight gain with antidepressants and lithium. J Clin Psychopharmacol. 1988;8: 323e330.
Aronson R, Offman HJ, Joffe RT, Naylor CD. Triiodothyronine augmentation in the treatment of refractory depression. A meta-analysis. Arch Gen Psychiatry. 1996;53: 842e848
DeBattista C, Doghramji K, Menza MA, Rosenthal MH, Fieve RR. Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary double-blind, placebo-controlled study. J Clin Psychiatry. 2003;64:1057e1064.
| onix_3.0::thoth | Thoth ONIX 3.0 |
|---|---|
| onix_3.0::project_muse | Project MUSE ONIX 3.0 |
| onix_3.0::oapen | OAPEN ONIX 3.0 |
| onix_3.0::jstor | JSTOR ONIX 3.0 |
| onix_3.0::google_books | Google Books ONIX 3.0 |
| onix_3.0::overdrive | OverDrive ONIX 3.0 |
| onix_2.1::ebsco_host | EBSCO Host ONIX 2.1 |
| csv::thoth | Thoth CSV |
| json::thoth | Thoth JSON |
| kbart::oclc | OCLC KBART |
| bibtex::thoth | Thoth BibTeX |
| doideposit::crossref | CrossRef DOI deposit |
| onix_2.1::proquest_ebrary | ProQuest Ebrary ONIX 2.1 |
| marc21record::thoth | Thoth MARC 21 Record |
| marc21markup::thoth | Thoth MARC 21 Markup |
| marc21xml::thoth | Thoth MARC 21 XML |
